Recruiting clinical trials in CH

Sotorasib (AMG 510)

Covalent KRASG12C inhibitor
Phase Ib/II
Combination
none (only outside of CH)
Indication
Tumor agnostic
CodeBreak 100
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation
Amgen protocol ID 20170543
Status Switzerland
Phase 2 fully enrolled; new NSCLC sub-study opening in Q2 2021
Centers, Principal Investigators (PI):
USB, S. Rothschild
USZ, A. Curioni
HUG, A. Addeo
Sotorasib (AMG 510)

Covalent KRASG12C inhibitor
Phase III
Combination
none
Indication
NSCLC
CodeBreak 200
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 (sotorasib) Versus Docetaxel for the treatment of Previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C.
Amgen protocol ID 20190009
Status Switzerland
Enrollment closed
Centers, PI:
KSW, M. Pless
USZ, A. Curioni
Inselspital, S. Häfliger
HUG, A. Addeo
CHUV, S. Peters
USB, S. Rothschild

For patients that do not qualify for the CodeBreak 100 or 200 trial, please contact Eva Vollenweider (evollenw@amgen.com) or Carine Bast (cepple@amgen.com) to evaluate further options (Named Patient Programme).
AMG 757

DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase I
Combination
+/- Pembrolizumab
Indication
SCLC
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Amgen protocol ID 20160323
Status Switzerland
Screening and recruitment ongoing
Centers, PI:
CHUV, S. Peters
T-VEC

Oncolytic Virus
Phase I/II
Combination
+ Pembrolizumab
Indication
BrCa (ER+, TNBC), CRC, HCC, BCC, CSCC
MASTERKEY-318
A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Amgen protocol ID 20140318
Status Switzerland
Phase 1: Recruiting HCC
Phase 2: Recruiting
Centers, PI:
KSW, M. Pless
USZ, R. Fritsch
CHUV, A. Digklia
HUG, N. Mach
T-VEC

Oncolytic Virus
Phase I
Combination
none
Indication
Pediatric
A Phase 1, Multicenter, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Amgen protocol ID 20110261
Status Switzerland
Recruiting
Centers, PI:
Universitäts-Kinderspital Zürich, N. Gerber
USB, T. Kühne

For further questions relating to the study programme, please contact Carine Bast or Eva Vollenweider

Nutzungsbedingungen:
Die medizinisch-wissenschaftlichen Informationen auf dieser Website science.amgen.ch sind ausschliesslich für medizinisches Fachpersonal aus der Schweiz bestimmt.

Ich bin kein Angehörige(r) des medizinischen Fachpersonals aus der Schweiz.